Search company, investor...

Founded Year




Total Raised


Date of IPO


Market Cap


Stock Price




About Celladon

Celladon is a biotechnology company developing molecular therapies for the treatment of heart failure. The company's products target the key enzyme deficiency in advanced heart failure, SERCA2a, which regulates calcium cycling and contractility in heart muscle cells. Celladon's initial product candidate, MYDICAR, delivers the gene for the SERCA2a enzyme. Celladon also develops small molecule activators of SERCA2a for acute heart failure.

Headquarters Location

12760 High Bluff Drive Suite 240

San Diego, California, 92130,

United States




Celladon Patents

Celladon has filed 6 patents.

patents chart

Application Date

Grant Date


Related Topics




Cardiac anatomy, Molecular biology, Heart diseases, Cardiac arrhythmia, Biotechnology


Application Date


Grant Date



Related Topics

Cardiac anatomy, Molecular biology, Heart diseases, Cardiac arrhythmia, Biotechnology



Latest Celladon News

Gene therapy market size to grow by USD 4,613.9 million from 2022 to 2027 | Growing research in gene therapy for CVDs and orphan diseases is the major market trend- Technavio

Dec 1, 2023

| Growing research in gene therapy for CVDs and orphan diseases is the major market trend- Technavio News provided by Share this article Share toX NEW YORK, Dec. 1, 2023 /PRNewswire/ -- Technavio categorizes the global gene therapy market  size as estimated to increase by USD 4,613.9 million between 2022 and 2027. The market's growth momentum will be progressing at a CAGR of 19.91% during the forecast period. Growing research in gene therapy for CVDs and orphan diseases is one of the key market trends that is contributing to the market growth. Due to the high prevalence of cardiovascular disease in adult patients over the age of 65, companies are shifting their R&D efforts toward developing gene therapies for these diseases. Coronary artery disease and heart failure require immediate treatment. Companies are therefore working to develop gene therapies that are administered to patients using viral vectors to angiogenic growth factors to promote collateral vessel development. For example, MYDICAR, a gene transfer therapy, is in Phase II development of Celladon for the treatment of heart failure. Such factors drive market growth during the forecast period. Discover some insights on market size historic data (2017 to 2021) and Forecast (2023 to 2027) before buying the full report -  Request a sample report Global Gene Therapy Market - Segmentation Assessment Segment Overview Technavio has segmented the market based on therapy areas (oncology, CNS, ophthalmology, rare diseases, and others), and delivery mode (in vivo and ex vivo). The market growth in the oncology segment will be significant during the forecast period. The global oncology drugs market has a huge unmet demand for the treatment of various indications. Also, the increasing prevalence of cancer indications has led pharmaceutical companies and research institutions to conduct extensive research to develop drugs for these indications. The lack of efficacy of small molecules and biomolecules has led companies to move towards effective therapeutic options such as gene therapy. Such factors will increase the segment growth during the forecast period. Geography Overview By geography, the global gene therapy market is segmented into North America, Europe, Asia, and Rest of World (ROW). The report provides actionable insights and estimates the contribution of all regions to the growth of the global gene therapy market. North America is estimated to contribute 39% to the growth of the global gene therapy market during the forecast period. The US has become a lucrative market for increased investment in the North American gene therapy market. This comes from government agencies such as the National Institutes of Health (NIH) and the Biomedical Advanced Research and Development Authority (BARDA) providing funding to small industries and companies focused on developing new products. Moreover, increasing funding from government and private organizations will drive the development of gene therapy during the forecast period. For insights on global, regional, and country-level parameters with growth opportunities from 2017 to 2027 -  Download a Sample Report Global Gene therapy market – Vendor Analysis Vendor Landscape - The global gene therapy market is fragmented, with the presence of several global as well as regional vendors. A few prominent vendors that offer gene therapy in the market are Abeona Therapeutics Inc., Adaptimmune Therapeutics plc, Adverum Biotechnologies Inc., Amgen Inc., Astellas Pharma Inc., Biogen Inc., bluebird bio Inc., Editas Medicine Inc., ElevateBio, F. Hoffmann La Roche Ltd., Generation Bio Co., Gilead Sciences Inc., Novartis AG, Orchard Therapeutics Plc, Poseida Therapeutics Inc., Sangamo Therapeutics Inc., Sibiono GeneTech Co. Ltd., Syncona Ltd., uniQure NV, and Voyager Therapeutics Inc. and others. A few prominent vendors that offer secure access service edge services in the market include: Abeona Therapeutics Inc.: The company offers gene therapy solutions such as Phase 3 VIITAL Clinical Trial of EB 101. Amgen Inc.: The company offers gene therapy solutions such as CAR T cell immunotherapies. Astellas Pharma Inc.: The company offers gene therapy solutions such as AT132, AT845, AT466. Biogen Inc.: The company offers gene therapy solutions such as GTxAU. What's New? - Special coverage on the Russia-Ukraine war; global inflation; recovery analysis from COVID-19; supply chain disruptions, global trade tensions; and risk of recession Global competitiveness and key competitor positions Market presence across multiple geographical footprints - Strong/Active/Niche/Trivial -  Buy the report! Global Gene Therapy Market – Market Dynamics Key Driver - The growth of the market is driven by the increase in special drug designations. Most gene therapy programs have been granted orphan drug designation, fast track designation, or breakthrough designation by the U.S. FDA, EMA, and other regulatory bodies for the treatment of certain diseases. In addition, orphan drug status will also help the company with tax incentives in its next research. Such advantages of specialty drug designations will drive the growth of the market during the forecast period. Major challenges - High treatment cost is one of the factors hindering the gene therapy market growth. Gene therapy costs range from USD 3 million to USD 1.2 million. Unlike other biomolecules and small molecules, gene therapy works differently for every individual and needs to be tailored separately for each. A mutated gene in a cell is taken from a patient and modified in the laboratory. The modified stem cells are introduced into the patient using a viral vector that is administered intravenously. This increases manufacturing costs and thus the overall cost of gene therapy. Such rising costs will be a challenging factor for the growth of the gene therapy market during the forecast period. Driver, Trend & Challenges are the factor of market dynamics which states about consequences & sustainability of the businesses, find some insights from a  sample report! What are the key data covered in this Gene Therapy Market report? CAGR of the market during the forecast period Detailed information on factors that will drive the growth of the gene therapy market between 2023 and 2027 Precise estimation of the gene therapy market size and its contribution to the market in focus on the parent market Accurate predictions about upcoming trends and changes in consumer behavior Growth of the gene therapy market across North America, Europe, Asia, and Rest of World (ROW) A thorough analysis of the market's competitive landscape and detailed information about vendors Comprehensive analysis of factors that will challenge the growth of gene therapy market vendors Gain instant access to 17,000+ market research reports. Related Reports: The cell and gene therapy market  size is expected to increase by USD 9.97 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 20.15%. The cell therapy market size is expected to increase by USD 21.061 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 56.79%. TOC market Segmentation by Delivery Mode Customer Landscape About US Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios. Contact

Celladon Frequently Asked Questions (FAQ)

  • When was Celladon founded?

    Celladon was founded in 2000.

  • Where is Celladon's headquarters?

    Celladon's headquarters is located at 12760 High Bluff Drive, San Diego.

  • What is Celladon's latest funding round?

    Celladon's latest funding round is IPO.

  • How much did Celladon raise?

    Celladon raised a total of $117.81M.

  • Who are the investors of Celladon?

    Investors of Celladon include Enterprise Partners Venture Capital, GBS Venture Partners, Lundbeckfond Ventures, Novartis Venture Funds, Pfizer Venture Investments and 10 more.

  • Who are Celladon's competitors?

    Competitors of Celladon include Erydel, Sagent Pharmaceuticals, Vapore, Carbylan Therapeutics, Transcept Pharmaceuticals and 7 more.


Compare Celladon to Competitors

MAD Nanolayers

MAD Nanolayers aims to provide a patented coating technology for delivering multiple agents sequentially and with precise control over dosage and timing. This is a platform technology with many therapeutic and non-therapeutic applications and whose disruptive feature is not available in any other coating technology today. MAD Nanolayers' primary offering will be a therapeutic coating for orthopedic implants that aims to deliver painkillers, antibiotics, and growth factors to minimize post-surgical complications and aims to eliminate subsequent re-intervention procedures, resulting in cost-savings to the hospitals and improved quality of life for patients.


Medi-Stream Pty Limited designs, develops and commercializes drug delivery technologies and devices focused on "˜Air Stream Medication'. The first commercial product released to the market is an Asthma medication delivery device, which has been soft launched to pharmacies under the trade name of Sportshaler. Innovation Capital committed to a $2.5m investment in April 2008.

Talima Therapeutics

Talima Therapeutics is an emerging drug delivery company dedicated to the development of novel products that increase patient choice and improve quality of life. With a unique approach to therapy, we design customized drug-delivery systems that optimize the local therapeutic performance and reduce the undesired systemic side effects enabling us to address unmet needs or underserved markets. We foster a collaborative environment and strive for excellence internally and with our partners. Our lead product is currently in Phase I/II clinical testing for the treatment of onychomycosis, a fungal disease of the nails and we are in the process of planning its pivotal trials.

Mirus Bio Logo
Mirus Bio

Mirus Bio is a company that specializes in the development of transfection reagents and proprietary technologies for nucleic acid delivery applications, operating within the biotechnology and life sciences industry. The company's main offerings include solutions for the production of viral vectors, manufacturing of recombinant proteins and monoclonal antibodies, and gene editing technologies. Mirus Bio primarily serves the cell and gene therapy industry. It was founded in 1995 and is based in Madison, Wisconsin.

Point Biomedical

POINT Biomedical is a privately held pharmaceutical company, founded to pursue technologies related to imaging and drug delivery. POINT's core technology is based upon an ultrasonically responsive two-layer, biodegradable microsphere or biSphere. One of the most important features of this technology is the ability to noninvasively trigger the biSpheres to release their contents at sites within the body using externally generated pulses of ultrasound. From this basic platform, POINT is developing a pipeline of products that leverage the unique properties of the biSphere technology in the areas of imaging and therapeutics. POINT has initially focused development of this platform on the assessment of tissue specific blood flow. The lead product, CARDIOsphere, is a pharmaceutical agent that will enable cardiologists to perform myocardial perfusion imaging studies in the office setting using ultrasound rather than more expensive and cumbersome nuclear (or radioisotope) techniques.


Medlogics is an early stage medical device company developing a broad platform technology for drug delivery. The initial focus is product development of polymer-free stent drug delivery.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.